GCA
SAGE

Gideon Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Gideon Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,276
Closed -$321K – 493
2018
Q3 		$321K Buy
+2,276
New +$351K 0.15% 225

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gideon Capital Advisors's SAGE Position: Q4 2018 in Review

Gideon Capital Advisors sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 2,276 shares — an estimated $321K sold.

Gideon Capital Advisors first reported a position in SAGE in Q3 2018 and held it in 1 quarter. The position peaked at $321K in Q3 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Gideon Capital Advisors reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 2,276 Sage Therapeutics shares in Q4 2018, an estimated $321K.
  • Gideon Capital Advisors first reported a position in Sage Therapeutics in Q3 2018 and held it in 1 quarter.
  • Gideon Capital Advisors's Sage Therapeutics position peaked at $321K in Q3 2018.
  • 248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.